- Supported exchanges /
- F /
- 48Q.F
X4 PHARMACEUTIC. DL-001 (48Q F) stock market data APIs
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
X4 PHARMACEUTIC. DL-001 Financial Data Overview
| 0.4408 | |
| 0.4408 | |
| - | |
| 0.4408 | |
| 0.4408 | |
| 0.4278-1.35 | |
| 78 024 K | |
| 3.6817 | |
| 169 M | |
| 563 K | |
| -0.74 | |
| 0.357 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
X4 PHARMACEUTIC. DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 563 K
- EBITDA -123 177 000
- Earnings Per Share 0.12
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get X4 PHARMACEUTIC. DL-001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.74
Get X4 PHARMACEUTIC. DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
